GlassScriptPhysician profile
Michael I Margolis
NPI 1346204203
$10,801.96
in general payments reported to CMS, 2019-2025
47 companies · $49.92 in 2025
The $49.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $1,567 · 2021: $1,930 · 2022: $1,230 · 2023: $1,275 · 2024: $3,001 · 2025: $49.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246 · Travel and Lodging: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.79 |
| Travel and Lodging | $2,080.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,080.21 | 2024 | |
| Glaxosmithkline, LLC. | $919.46 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $847.52 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $761.32 | 2019-2023 | Rybelsus |
| Abbvie INC. | $742.10 | 2019-2023 | |
| Lilly USA, LLC | $568.71 | 2019-2024 | Mounjaro, Zepbound, Lyumjev |
| Amgen INC. | $511.22 | 2019-2024 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $487.76 | 2021-2024 | |
| Pfizer INC. | $461.08 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.12 | 2019-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $283.51 | 2019-2021 | |
| Amarin Pharma, INC. | $236.66 | 2019-2022 | |
| Allergan, INC. | $207.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.52 | 2019-2024 | Jardiance, Synjardy, Glyxambi |
| Sanofi-Aventis U.S. LLC | $185.92 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.